Clearview Cancer Institute

Recent papers from Clearview Cancer Institute

1. Diagnostic imaging and emerging image-guided neurointervention in brain tumors: a narrative reviewFrontiers in Radiology · 2026
2. Insights into the impact of base-excision–repair genes on immunotherapy response in solid tumors.Journal of Clinical Oncology · 2026
3. Comparative toxicity profile of chimeric antigen receptor T-cell therapy versus bispecific T-cell engagers in multiple myeloma and B-cell lymphomas: A propensity-matched real-world analysis.Journal of Clinical Oncology · 2026
4. Early operative management versus nonoperative care for cancer-associated small bowel obstruction in patients with recent peritoneal metastasis: A real-world propensity-matched analysis.Journal of Clinical Oncology · 2026
5. Feasibility assessment of an EHR-integrated research platform for prospective data collection in community oncology practicenpj Health Systems · 2026
6. Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced MelanomaClinical Cancer Research · 2025
7. Identifying risk factors associated with self-reported lower quality of life (QoL) in individuals with PTEN hamartoma tumor syndrome.Journal of Clinical Oncology · 2024
8. A Rare Case Report of Amiodarone-Induced Bone Marrow GranulomaAnnals of Internal Medicine Clinical Cases · 2024
9. Treatment with chemotherapy plus brentuximab vedotin in anaplastic large cell lymphoma and pregnancy: A case reportJournal of Case Reports and Images in Oncology · 2024
10. Public awareness of the association between the risk of breast cancer (BC) development and alcohol consumption (AC) among women aged 18–75 years.Journal of Clinical Oncology · 2024
11. Advanced Materials and Additive Manufacturing for Phase Change Thermal Energy Storage and Management: A ReviewAdvanced Energy Materials · 2023
12. Improved Treatment Effect of Triamcinolone Acetonide Extended-Release in Patients with Concordant Baseline Pain Scores on the Average Daily Pain and Western Ontario and McMaster Universities Osteoarthritis Index Pain ScalesPain and Therapy · 2021
13. Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancerJournal for ImmunoTherapy of Cancer · 2021
14. The In-Betweeners: A Focus on Young Adults with CancerOncology Issues · 2020
15. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemiaBlood · 2019
16. Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor ActivityClinical Cancer Research · 2019
17. Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagementJCI Insight · 2018
18. Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic LeukemiaHemaSphere · 2018
19. Acute Graft Versus Host Disease: A Comprehensive ReviewAnticancer Research · 2017
20. A phase 1/2 trial of ublituximab, a novel anti‐ CD 20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximabBritish Journal of Haematology · 2017